The New York Times reports:
AstraZeneca reiterated on Wednesday that its Covid-19 vaccine was very effective at preventing the disease, based on more recent data than was included when the company announced the interim results of its U.S. clinical trial on Monday.
The company said in a news release that its vaccine was 76 percent effective at preventing Covid-19. That is slightly lower than the efficacy number that the company announced earlier this week.
The new results strengthen the scientific case for the embattled vaccine. But they may not repair the damage to AstraZeneca’s credibility after U.S. health officials and independent monitors issued an extraordinary rebuke of the company for not counting some Covid-19 cases when it announced its initial findings this week.
Read the full article.
AstraZeneca reiterated that its coronavirus vaccine was very effective at preventing the disease, saying the shot was 76% effective — just slightly lower than the number it announced earlier this week. https://t.co/HuLfe4iUsn
— The New York Times (@nytimes) March 25, 2021